ALN-6400 + Placebo
Phase 1/2Recruiting 0 watching 0 views this week💤 Quiet
38
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Hereditary Hemorrhagic Telangiectasia
Conditions
Hereditary Hemorrhagic Telangiectasia
Trial Timeline
Nov 7, 2024 → Jun 22, 2028
NCT ID
NCT06659640About ALN-6400 + Placebo
ALN-6400 + Placebo is a phase 1/2 stage product being developed by Alnylam Pharmaceuticals for Hereditary Hemorrhagic Telangiectasia. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06659640. Target conditions include Hereditary Hemorrhagic Telangiectasia.
Hype Score Breakdown
Clinical
13
Activity
8
Company
7
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06659640 | Phase 1/2 | Recruiting |
Competing Products
20 competing products in Hereditary Hemorrhagic Telangiectasia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| KVD900 | KalVista Pharmaceuticals | Phase 2 | 47 |
| KVD824 + Placebo to KVD824 | KalVista Pharmaceuticals | Phase 1 | 28 |
| KVD900 600 mg + KVD900 300 mg | KalVista Pharmaceuticals | Phase 3 | 72 |
| Sebetralstat | KalVista Pharmaceuticals | Pre-clinical | 18 |
| KVD900 + Placebo to KVD900 | KalVista Pharmaceuticals | Phase 1 | 28 |
| Sebetralstat | KalVista Pharmaceuticals | Pre-clinical | 18 |
| Placebo + KVD900 600 mg + KVD900 300 mg | KalVista Pharmaceuticals | Phase 3 | 72 |
| KVD824 Prototype 1 modified-release tablet + KVD824 Prototype 2 modified-release tablet + KVD824 Immediate-Release Capsule + Placebo to KVD824 Prototype 1 + KVD824 Prototype 3 modified-release tablet | KalVista Pharmaceuticals | Phase 1 | 28 |
| KVD900 150 mg + KVD900 300 mg + KVD900 600 mg | KalVista Pharmaceuticals | Phase 3 | 72 |
| KVD824 + Placebo to KVD824 | KalVista Pharmaceuticals | Phase 2 | 47 |
| KVD900 600 mg + Drug: KVD900 300 mg | KalVista Pharmaceuticals | Phase 3 | 72 |
| Deferasirox FCT | Novartis | Phase 2 | 52 |
| Canakinumab + Placebo | Novartis | Phase 3 | 77 |
| Ilaris | Novartis | Pre-clinical | 23 |
| Standard of Care for Haemophilia A | Roche | Pre-clinical | 23 |
| Emicizumab | Roche | Phase 3 | 77 |
| Tafamidis | Pfizer | Pre-clinical | 22 |
| tafamidis | Pfizer | Pre-clinical | 22 |
| Nitisinone | Swedish Orphan Biovitrum | Pre-clinical | 22 |
| Nitisinone | Swedish Orphan Biovitrum | Phase 1 | 32 |